Table 6.

Clinical Questions Evaluated

Question	Population	Intervention	Comparison	Outcome(s)
1	Immune-active CHB	Antiviral therapy	No treatment	Cirrhosis, decompensation, HCC, death, loss of HBsAg
2	Immune-tolerant CHB, adults	Antiviral therapy	No treatment	Cirrhosis, decompensation, HCC, death, loss of HBsAg
3	HBeAg-positive immune-active chronic hepatitis, with HBeAg seroconversion on therapy	Continued antiviral therapy	Stopping antiviral therapy	Cirrhosis, HCC, reactivation, seroreversion, decompensation, loss of HBsAg
4	HBeAg-negative immune-active chronic hepatitis, with viral suppression on antiviral therapy	Continued antiviral therapy	Stopping antiviral therapy	Reactivation, decompensation, loss of HBsAg
5	CHB on treatment with oral therapy	Tenofovir	Entecavir	Renal function, hypophosphatemia, bone health
6	CHB on treatment with oral therapy with persistent viremia	Continue therapy	Change or switch therapy	HBV resistance, clinical flare, decompensation, loss of HBeAg
7	CHB with cirrhosis, with HBV DNA <2,000 IU/mL	Antiviral therapy	No treatment	Decompensation, HCC, death
8	Pregnant women with CHB	Antiviral therapy in third trimester	No treatment	CHB in the infant, maternal safety, fetal/infant safety
9	HBeAg-positive CHB, children/adolescents	Antiviral therapy	No treatment	Cirrhosis, decompensation, HCC, death, HBeAg seroconversion, loss of HBsAg